About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Gene Therapy Market Size, Global Trends, Top Share, Forecast to 2033
Gene Therapy Market

Gene Therapy Market Size, Share & Trends Analysis Report By Type (Gene silencing, Cell replacement, Gene augmentation, Other therapies), By Vector (Viral vectors, Non-Viral vectors), By Therapeutic area (Neurology, Oncology, Hepatology, Other therapeutic areas), By Delivery method (In Vivo, Ex Vivo), By Route of administration (Intravenous, Other routes of administration), By Indication (Cancer, Metabolic Disorders, Eye Disorders, Spinal Muscular Atrophy, Other Indications), By Technology (Adeno Virus Vector, Adeno-associated Virus Vector, Lentiviral Vector, Retroviral Vector, Herpes Virus Vector, Other Technologies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI55205DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Gene Therapy Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Gene silencing
        1. By Value
      3. Cell replacement
        1. By Value
      4. Gene augmentation
        1. By Value
      5. Other therapies
        1. By Value
    3. By Vector
      1. Introduction
        1. Vector By Value
      2. Viral vectors
        1. By Value
      3. Non-Viral vectors
        1. By Value
    4. By Therapeutic area
      1. Introduction
        1. Therapeutic area By Value
      2. Neurology
        1. By Value
      3. Oncology
        1. By Value
      4. Hepatology
        1. By Value
      5. Other therapeutic areas
        1. By Value
    5. By Delivery method
      1. Introduction
        1. Delivery method By Value
      2. In Vivo
        1. By Value
      3. Ex Vivo
        1. By Value
    6. By Route of administration
      1. Introduction
        1. Route of administration By Value
      2. Intravenous
        1. By Value
      3. Other routes of administration
        1. By Value
    7. By Indication
      1. Introduction
        1. Indication By Value
      2. Cancer
        1. By Value
      3. Metabolic Disorders
        1. By Value
      4. Eye Disorders
        1. By Value
      5. Spinal Muscular Atrophy
        1. By Value
      6. Other Indications
        1. By Value
    8. By Technology
      1. Introduction
        1. Technology By Value
      2. Adeno Virus Vector
        1. By Value
      3. Adeno-associated Virus Vector
        1. By Value
      4. Lentiviral Vector
        1. By Value
      5. Retroviral Vector
        1. By Value
      6. Herpes Virus Vector
        1. By Value
      7. Other Technologies
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Gene silencing
        1. By Value
      3. Cell replacement
        1. By Value
      4. Gene augmentation
        1. By Value
      5. Other therapies
        1. By Value
    3. By Vector
      1. Introduction
        1. Vector By Value
      2. Viral vectors
        1. By Value
      3. Non-Viral vectors
        1. By Value
    4. By Therapeutic area
      1. Introduction
        1. Therapeutic area By Value
      2. Neurology
        1. By Value
      3. Oncology
        1. By Value
      4. Hepatology
        1. By Value
      5. Other therapeutic areas
        1. By Value
    5. By Delivery method
      1. Introduction
        1. Delivery method By Value
      2. In Vivo
        1. By Value
      3. Ex Vivo
        1. By Value
    6. By Route of administration
      1. Introduction
        1. Route of administration By Value
      2. Intravenous
        1. By Value
      3. Other routes of administration
        1. By Value
    7. By Indication
      1. Introduction
        1. Indication By Value
      2. Cancer
        1. By Value
      3. Metabolic Disorders
        1. By Value
      4. Eye Disorders
        1. By Value
      5. Spinal Muscular Atrophy
        1. By Value
      6. Other Indications
        1. By Value
    8. By Technology
      1. Introduction
        1. Technology By Value
      2. Adeno Virus Vector
        1. By Value
      3. Adeno-associated Virus Vector
        1. By Value
      4. Lentiviral Vector
        1. By Value
      5. Retroviral Vector
        1. By Value
      6. Herpes Virus Vector
        1. By Value
      7. Other Technologies
        1. By Value
    9. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Gene silencing
          1. By Value
        3. Cell replacement
          1. By Value
        4. Gene augmentation
          1. By Value
        5. Other therapies
          1. By Value
      2. By Vector
        1. Introduction
          1. Vector By Value
        2. Viral vectors
          1. By Value
        3. Non-Viral vectors
          1. By Value
      3. By Therapeutic area
        1. Introduction
          1. Therapeutic area By Value
        2. Neurology
          1. By Value
        3. Oncology
          1. By Value
        4. Hepatology
          1. By Value
        5. Other therapeutic areas
          1. By Value
      4. By Delivery method
        1. Introduction
          1. Delivery method By Value
        2. In Vivo
          1. By Value
        3. Ex Vivo
          1. By Value
      5. By Route of administration
        1. Introduction
          1. Route of administration By Value
        2. Intravenous
          1. By Value
        3. Other routes of administration
          1. By Value
      6. By Indication
        1. Introduction
          1. Indication By Value
        2. Cancer
          1. By Value
        3. Metabolic Disorders
          1. By Value
        4. Eye Disorders
          1. By Value
        5. Spinal Muscular Atrophy
          1. By Value
        6. Other Indications
          1. By Value
      7. By Technology
        1. Introduction
          1. Technology By Value
        2. Adeno Virus Vector
          1. By Value
        3. Adeno-associated Virus Vector
          1. By Value
        4. Lentiviral Vector
          1. By Value
        5. Retroviral Vector
          1. By Value
        6. Herpes Virus Vector
          1. By Value
        7. Other Technologies
          1. By Value
    10. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Gene silencing
        1. By Value
      3. Cell replacement
        1. By Value
      4. Gene augmentation
        1. By Value
      5. Other therapies
        1. By Value
    3. By Vector
      1. Introduction
        1. Vector By Value
      2. Viral vectors
        1. By Value
      3. Non-Viral vectors
        1. By Value
    4. By Therapeutic area
      1. Introduction
        1. Therapeutic area By Value
      2. Neurology
        1. By Value
      3. Oncology
        1. By Value
      4. Hepatology
        1. By Value
      5. Other therapeutic areas
        1. By Value
    5. By Delivery method
      1. Introduction
        1. Delivery method By Value
      2. In Vivo
        1. By Value
      3. Ex Vivo
        1. By Value
    6. By Route of administration
      1. Introduction
        1. Route of administration By Value
      2. Intravenous
        1. By Value
      3. Other routes of administration
        1. By Value
    7. By Indication
      1. Introduction
        1. Indication By Value
      2. Cancer
        1. By Value
      3. Metabolic Disorders
        1. By Value
      4. Eye Disorders
        1. By Value
      5. Spinal Muscular Atrophy
        1. By Value
      6. Other Indications
        1. By Value
    8. By Technology
      1. Introduction
        1. Technology By Value
      2. Adeno Virus Vector
        1. By Value
      3. Adeno-associated Virus Vector
        1. By Value
      4. Lentiviral Vector
        1. By Value
      5. Retroviral Vector
        1. By Value
      6. Herpes Virus Vector
        1. By Value
      7. Other Technologies
        1. By Value
    9. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Gene silencing
          1. By Value
        3. Cell replacement
          1. By Value
        4. Gene augmentation
          1. By Value
        5. Other therapies
          1. By Value
      2. By Vector
        1. Introduction
          1. Vector By Value
        2. Viral vectors
          1. By Value
        3. Non-Viral vectors
          1. By Value
      3. By Therapeutic area
        1. Introduction
          1. Therapeutic area By Value
        2. Neurology
          1. By Value
        3. Oncology
          1. By Value
        4. Hepatology
          1. By Value
        5. Other therapeutic areas
          1. By Value
      4. By Delivery method
        1. Introduction
          1. Delivery method By Value
        2. In Vivo
          1. By Value
        3. Ex Vivo
          1. By Value
      5. By Route of administration
        1. Introduction
          1. Route of administration By Value
        2. Intravenous
          1. By Value
        3. Other routes of administration
          1. By Value
      6. By Indication
        1. Introduction
          1. Indication By Value
        2. Cancer
          1. By Value
        3. Metabolic Disorders
          1. By Value
        4. Eye Disorders
          1. By Value
        5. Spinal Muscular Atrophy
          1. By Value
        6. Other Indications
          1. By Value
      7. By Technology
        1. Introduction
          1. Technology By Value
        2. Adeno Virus Vector
          1. By Value
        3. Adeno-associated Virus Vector
          1. By Value
        4. Lentiviral Vector
          1. By Value
        5. Retroviral Vector
          1. By Value
        6. Herpes Virus Vector
          1. By Value
        7. Other Technologies
          1. By Value
    10. Germany
    11. France
    12. Spain
    13. Italy
    14. Russia
    15. Nordic
    16. Benelux
    17. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Gene silencing
        1. By Value
      3. Cell replacement
        1. By Value
      4. Gene augmentation
        1. By Value
      5. Other therapies
        1. By Value
    3. By Vector
      1. Introduction
        1. Vector By Value
      2. Viral vectors
        1. By Value
      3. Non-Viral vectors
        1. By Value
    4. By Therapeutic area
      1. Introduction
        1. Therapeutic area By Value
      2. Neurology
        1. By Value
      3. Oncology
        1. By Value
      4. Hepatology
        1. By Value
      5. Other therapeutic areas
        1. By Value
    5. By Delivery method
      1. Introduction
        1. Delivery method By Value
      2. In Vivo
        1. By Value
      3. Ex Vivo
        1. By Value
    6. By Route of administration
      1. Introduction
        1. Route of administration By Value
      2. Intravenous
        1. By Value
      3. Other routes of administration
        1. By Value
    7. By Indication
      1. Introduction
        1. Indication By Value
      2. Cancer
        1. By Value
      3. Metabolic Disorders
        1. By Value
      4. Eye Disorders
        1. By Value
      5. Spinal Muscular Atrophy
        1. By Value
      6. Other Indications
        1. By Value
    8. By Technology
      1. Introduction
        1. Technology By Value
      2. Adeno Virus Vector
        1. By Value
      3. Adeno-associated Virus Vector
        1. By Value
      4. Lentiviral Vector
        1. By Value
      5. Retroviral Vector
        1. By Value
      6. Herpes Virus Vector
        1. By Value
      7. Other Technologies
        1. By Value
    9. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Gene silencing
          1. By Value
        3. Cell replacement
          1. By Value
        4. Gene augmentation
          1. By Value
        5. Other therapies
          1. By Value
      2. By Vector
        1. Introduction
          1. Vector By Value
        2. Viral vectors
          1. By Value
        3. Non-Viral vectors
          1. By Value
      3. By Therapeutic area
        1. Introduction
          1. Therapeutic area By Value
        2. Neurology
          1. By Value
        3. Oncology
          1. By Value
        4. Hepatology
          1. By Value
        5. Other therapeutic areas
          1. By Value
      4. By Delivery method
        1. Introduction
          1. Delivery method By Value
        2. In Vivo
          1. By Value
        3. Ex Vivo
          1. By Value
      5. By Route of administration
        1. Introduction
          1. Route of administration By Value
        2. Intravenous
          1. By Value
        3. Other routes of administration
          1. By Value
      6. By Indication
        1. Introduction
          1. Indication By Value
        2. Cancer
          1. By Value
        3. Metabolic Disorders
          1. By Value
        4. Eye Disorders
          1. By Value
        5. Spinal Muscular Atrophy
          1. By Value
        6. Other Indications
          1. By Value
      7. By Technology
        1. Introduction
          1. Technology By Value
        2. Adeno Virus Vector
          1. By Value
        3. Adeno-associated Virus Vector
          1. By Value
        4. Lentiviral Vector
          1. By Value
        5. Retroviral Vector
          1. By Value
        6. Herpes Virus Vector
          1. By Value
        7. Other Technologies
          1. By Value
    10. Korea
    11. Japan
    12. India
    13. Australia
    14. Singapore
    15. Taiwan
    16. South East Asia
    17. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Gene silencing
        1. By Value
      3. Cell replacement
        1. By Value
      4. Gene augmentation
        1. By Value
      5. Other therapies
        1. By Value
    3. By Vector
      1. Introduction
        1. Vector By Value
      2. Viral vectors
        1. By Value
      3. Non-Viral vectors
        1. By Value
    4. By Therapeutic area
      1. Introduction
        1. Therapeutic area By Value
      2. Neurology
        1. By Value
      3. Oncology
        1. By Value
      4. Hepatology
        1. By Value
      5. Other therapeutic areas
        1. By Value
    5. By Delivery method
      1. Introduction
        1. Delivery method By Value
      2. In Vivo
        1. By Value
      3. Ex Vivo
        1. By Value
    6. By Route of administration
      1. Introduction
        1. Route of administration By Value
      2. Intravenous
        1. By Value
      3. Other routes of administration
        1. By Value
    7. By Indication
      1. Introduction
        1. Indication By Value
      2. Cancer
        1. By Value
      3. Metabolic Disorders
        1. By Value
      4. Eye Disorders
        1. By Value
      5. Spinal Muscular Atrophy
        1. By Value
      6. Other Indications
        1. By Value
    8. By Technology
      1. Introduction
        1. Technology By Value
      2. Adeno Virus Vector
        1. By Value
      3. Adeno-associated Virus Vector
        1. By Value
      4. Lentiviral Vector
        1. By Value
      5. Retroviral Vector
        1. By Value
      6. Herpes Virus Vector
        1. By Value
      7. Other Technologies
        1. By Value
    9. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Gene silencing
          1. By Value
        3. Cell replacement
          1. By Value
        4. Gene augmentation
          1. By Value
        5. Other therapies
          1. By Value
      2. By Vector
        1. Introduction
          1. Vector By Value
        2. Viral vectors
          1. By Value
        3. Non-Viral vectors
          1. By Value
      3. By Therapeutic area
        1. Introduction
          1. Therapeutic area By Value
        2. Neurology
          1. By Value
        3. Oncology
          1. By Value
        4. Hepatology
          1. By Value
        5. Other therapeutic areas
          1. By Value
      4. By Delivery method
        1. Introduction
          1. Delivery method By Value
        2. In Vivo
          1. By Value
        3. Ex Vivo
          1. By Value
      5. By Route of administration
        1. Introduction
          1. Route of administration By Value
        2. Intravenous
          1. By Value
        3. Other routes of administration
          1. By Value
      6. By Indication
        1. Introduction
          1. Indication By Value
        2. Cancer
          1. By Value
        3. Metabolic Disorders
          1. By Value
        4. Eye Disorders
          1. By Value
        5. Spinal Muscular Atrophy
          1. By Value
        6. Other Indications
          1. By Value
      7. By Technology
        1. Introduction
          1. Technology By Value
        2. Adeno Virus Vector
          1. By Value
        3. Adeno-associated Virus Vector
          1. By Value
        4. Lentiviral Vector
          1. By Value
        5. Retroviral Vector
          1. By Value
        6. Herpes Virus Vector
          1. By Value
        7. Other Technologies
          1. By Value
    10. Turkey
    11. Saudi Arabia
    12. South Africa
    13. Egypt
    14. Nigeria
    15. The rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Gene silencing
        1. By Value
      3. Cell replacement
        1. By Value
      4. Gene augmentation
        1. By Value
      5. Other therapies
        1. By Value
    3. By Vector
      1. Introduction
        1. Vector By Value
      2. Viral vectors
        1. By Value
      3. Non-Viral vectors
        1. By Value
    4. By Therapeutic area
      1. Introduction
        1. Therapeutic area By Value
      2. Neurology
        1. By Value
      3. Oncology
        1. By Value
      4. Hepatology
        1. By Value
      5. Other therapeutic areas
        1. By Value
    5. By Delivery method
      1. Introduction
        1. Delivery method By Value
      2. In Vivo
        1. By Value
      3. Ex Vivo
        1. By Value
    6. By Route of administration
      1. Introduction
        1. Route of administration By Value
      2. Intravenous
        1. By Value
      3. Other routes of administration
        1. By Value
    7. By Indication
      1. Introduction
        1. Indication By Value
      2. Cancer
        1. By Value
      3. Metabolic Disorders
        1. By Value
      4. Eye Disorders
        1. By Value
      5. Spinal Muscular Atrophy
        1. By Value
      6. Other Indications
        1. By Value
    8. By Technology
      1. Introduction
        1. Technology By Value
      2. Adeno Virus Vector
        1. By Value
      3. Adeno-associated Virus Vector
        1. By Value
      4. Lentiviral Vector
        1. By Value
      5. Retroviral Vector
        1. By Value
      6. Herpes Virus Vector
        1. By Value
      7. Other Technologies
        1. By Value
    9. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Gene silencing
          1. By Value
        3. Cell replacement
          1. By Value
        4. Gene augmentation
          1. By Value
        5. Other therapies
          1. By Value
      2. By Vector
        1. Introduction
          1. Vector By Value
        2. Viral vectors
          1. By Value
        3. Non-Viral vectors
          1. By Value
      3. By Therapeutic area
        1. Introduction
          1. Therapeutic area By Value
        2. Neurology
          1. By Value
        3. Oncology
          1. By Value
        4. Hepatology
          1. By Value
        5. Other therapeutic areas
          1. By Value
      4. By Delivery method
        1. Introduction
          1. Delivery method By Value
        2. In Vivo
          1. By Value
        3. Ex Vivo
          1. By Value
      5. By Route of administration
        1. Introduction
          1. Route of administration By Value
        2. Intravenous
          1. By Value
        3. Other routes of administration
          1. By Value
      6. By Indication
        1. Introduction
          1. Indication By Value
        2. Cancer
          1. By Value
        3. Metabolic Disorders
          1. By Value
        4. Eye Disorders
          1. By Value
        5. Spinal Muscular Atrophy
          1. By Value
        6. Other Indications
          1. By Value
      7. By Technology
        1. Introduction
          1. Technology By Value
        2. Adeno Virus Vector
          1. By Value
        3. Adeno-associated Virus Vector
          1. By Value
        4. Lentiviral Vector
          1. By Value
        5. Retroviral Vector
          1. By Value
        6. Herpes Virus Vector
          1. By Value
        7. Other Technologies
          1. By Value
    10. Mexico
    11. Argentina
    12. Chile
    13. Colombia
    14. Rest of LATAM
    1. Gene Therapy Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. REGENXBIO, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Oxford BioMedica plc
    3. Dimension Therapeutics, Inc.
    4. Bristol-Myers Squibb Company
    5. SANOFI
    6. Applied Genetic Technologies Corporation
    7. F. Hoffmann-La Roche Ltd
    8. Bluebird Bio, Inc.
    9. Novartis AG
    10. Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
    11. UniQure N.V.
    12. Shire Plc
    13. Cellectis S.A.
    14. Sangamo Therapeutics, Inc
    15. Orchard Therapeutics
    16. Gilead Lifesciences, Inc.
    17. BENITEC BIOPHARMA
    18. Sibiono GeneTech Co., Ltd
    19. Shanghai Sunway Biotech Co., Ltd.
    20. Gensight Biologics S.A.
    21. Transgene
    22. Calimmune, Inc.
    23. Epeius Biotechnologies Corp.
    24. Astellas Pharma, Inc.
    25. American Gene Technologies
    26. BioMarin Pharmaceuticals, Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Cell and Gene Therapy Market Size The global cell and gene therapy market size was valued at USD 30.27 billion in 2024 and is projected to reach from USD 37.14 billion in 2025 to USD 190.82 billion by 2033, expanding at a&nb
Buy Now
Global Report
Electrotherapy Market Size The global electrotherapy market size was valued at USD 1265.85 million in 2024 and is projected to reach from USD 1331.67 million in 2025 to USD 1997.67 million by 2033, growing at
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.